Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia
2022-523-GLOB1
Phase 1 other active
Quick answer
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia for Primary immune thrombocytopenia (ITP) is a Phase 1 program (other) at Hutchmed Europe B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hutchmed Europe B.V.
- Indication
- Primary immune thrombocytopenia (ITP)
- Phase
- Phase 1
- Modality
- other
- Status
- active